Ambu A/S (AMBU-B) Fair Value & Analysis
Healthcare · DK · Market cap 18.1B DKK
Fair value as of: Jul 19, 2026
From 26 valuation models · updated 2 days ago
Fair value updated Jul 19, 2026, revised from kr 58.22 to kr 58.69 (+0.8%) since Jul 14, 2026. Share price +13.2% over the past month.
Price vs Fair Value (12 months)
12‑month range kr 60.95 – kr 107.19 · fair‑value band kr 40.87 – kr 73.36 · the kr 71.25 price screens above the kr 58.69 fair value. As of Jul 19, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Ambu A/S (AMBU-B) currently trades at kr 71.25, while our model-based Fair Value estimate is kr 58.69, implying the stock looks roughly 17.6% overvalued today. We read business quality at 55/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Ambu A/S generated revenue of 6.1B DKK at a net margin of 7.8%. Revenue grew 1.2% year over year. It earns a return on equity of 7.9%. The balance sheet holds a net cash position of 319M DKK. Fundamentals as of Jul 19, 2026
Our scenario range runs from kr 40.87 (bear case) to kr 73.36 (bull case); at kr 71.25, the current price sits within that range. The share trades about 36% below its 52-week high and 18% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at -18%, AMBU-B screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 19, 2026. TTM = trailing twelve months.
About the company
Ambu A/S, together with its subsidiaries, researches, develops, manufactures, markets, and sells medical technology solutions in North America, Europe, and internationally. The company offers endoscopy products, including bronchoscopes, video laryngoscopes, rhinolaryngoscopes, duodenoscopes, gastroscopes, cystoscopes, ureteroscopes, and displaying and processing units; neurology products, such as EEG and EMG electrodes, EMG guided injections, and intraoperative monitoring products; and cardiology products comprising ECG electrodes. It also provides airway management and anaesthesia products, which include double and single lumen tubes, endobronchial blockers, laryngeal and face masks, breathing bags, and resuscitators. In addition, the company offers emergency care and training products, such as extrication collars and ALS and BLS training manikins, as well as mobile workstations, IOMs, and patient monitoring and diagnostics devices. Ambu A/S was founded in 1937 and is …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Ambu A/S reported revenue of kr 6.0B in FY2025 versus kr 4.0B in FY2021, a compound +10.7%/yr. Reported net income was kr 609M in FY2025, compounding +25.3%/yr from FY2021.
Is AMBU-B fairly valued? → Check now
Recent news
- [Latest] Global Neonatal Intensive Care Respiratory Devices Market Size/Share Worth USD 5.7 Billion by 2035 at a 10.5% CAGR: Healthcare Fore
- [Latest] Global Gastrointestinal Endoscopy Devices Market Size/Share Worth USD 19.6 Billion by 2035 at a 5.4% CAGR: Healthcare Foresights (A
- Top European Growth Companies With High Insider Ownership In May 2026
- European Stocks Estimated Below Fair Value In May 2026
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection, not financial advice.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 19, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $86.97 | $69.36 | -20% |
| Stryker Corporation SYK | $305.66 | $187.83 | -39% |
| Medtronic plc MDTC34 | R$210.63 | R$24.08 | -89% |
| Boston Scientific Corporation B1SX34 | R$247.01 | R$234.82 | -5% |
| Edwards Lifesciences Corporation EWL | €74.64 | €31.98 | -57% |
| Siemens Healthineers AG SEMHF | $40.29 | $47.96 | +19% |
| DexCom, Inc DXCM | $74.77 | $53.93 | -28% |
| GE HealthCare Technologies Inc GEHC | $61.99 | $48.34 | -22% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥141.85 | ¥147.63 | +4% |
| Koninklijke Philips N.V PHG | $26.98 | $10.24 | -62% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Ambu A/S (AMBU-B) undervalued?
What is the fair value of AMBU-B?
What is the quality score of AMBU-B?
What is the revenue of Ambu A/S (AMBU-B)?
What is the net profit margin of AMBU-B?
Does Ambu A/S pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Ambu A/S analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.